Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in dMMR Colorectal Cancer in Nigeria
NCT06529523Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06529523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529523.